FDA Wins, Biotech Bets, and CRISPR Risk
Kilder
- BioPharma Dive: FDA approves Moderna’s mRNA flu vaccine
- The Wall Street Journal: FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review - WSJ
- Ajmc: FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success - ajmc.com
- Endpoints: Replimune wins FDA approval after melanoma drug was twice rejected
- Bloomberg: Twice-Rejected Replimune Cancer Drug Finally Gets FDA Nod - Bloomberg
- STAT: FDA approves Replimune melanoma drug previously rejected twice - STAT
- STAT: STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
- STAT: Two FDA approvals — a new drug and a new vaccine - STAT
- BioPharma Dive: With $263M, LifeMine unearths a new drug for organ transplants
- BioPharma Dive: Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive
- Endpoints: Intellia identifies genetic risk factor for liver complications in CRISPR trial
- BioSpace: The top 12 companies hiring in biopharma now
- wikimedia: Photo by Whispyhistory / Wikimedia Commons / CC BY-SA 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.